Ignite Creation Date:
2025-12-25 @ 5:11 AM
Ignite Modification Date:
2025-12-26 @ 4:17 AM
Study NCT ID:
NCT05832827
Status:
RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-04-16
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Sponsor:
National Cancer Center, Japan
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-04
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-04-16
First Submit QC Date:
None
Study First Post Date:
2023-04-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-18
Last Update Post Date:
2023-10-23
Last Update Post Date Type:
ACTUAL